Sign In / Join

close

HealthTree News

HealthTree News is a place to learn all about your disease in easy-to-understand language. The site features news articles, patient stories, basics articles, and clinical trial updates with new content every week.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Findings from an International Phase 3 Trial: Uproleselan for Relapsed/Refractory AML

February 17, 2025

Learn how uproleselan may improve treatment outcomes for relapsed or refractory acute myeloid leukemia patients in this latest clinical study.

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

February 14, 2025

A recent ASH study suggests that immediately starting treatment after an AML diagnosis may not always be necessary. Learn more!

Midostaurin for FLT3-Mutated AML, 10 Years Later

February 13, 2025

Learn about the 10-year benefits of midostaurin with chemotherapy for FLT3-mutated newly diagnosed AML.

Olutasidenib Study Results for Relapsed/Refractory AML

February 11, 2025

Data from ASH 2024 shows olutasidenib’s impact on AML patients with mIDH1, achieving 35% remission. Learn more about this promising treatment.

Study Highlights The Need for Risk Models in AML for Black Patients

February 06, 2025

New Research Highlights Need for More Inclusive Risk Models in AML, Especially for Black Patients

HealthTree Foundation Honors Leading Blood Cancer Researchers at ASH 2024 Awards Reception

February 04, 2025

HealthTree recognizes researchers with Innovation and Real-World Data Awards at ASH 2024, celebrating advancements in blood cancer research and patient care.

FDA Approval of Treosulfan for AML and MDS

February 02, 2025

FDA approves Treosulfan (Grafapex) for AML and MDS stem cell transplant conditioning, offering a new alternative to busulfan-based regimens.

An Opportunity to Take Action: Regional Cure Teams

January 31, 2025

We are excited to announce the launch of the HealthTree Regional Cure Teams—an opportunity for individuals to volunteer in their communities.

Understanding Barriers to CAR T-Cell Therapy for Blood Cancer Patients

January 31, 2025

If blood cancer patients are referred to receive CAR T-cell therapy, what barriers are keeping them from receiving it? Learn answers in this article.

Why Should You Quit Smoking If You Have MDS or AML?

January 30, 2025

Learn how smoking impacts myelodysplastic syndromes and acute myeloid leukemia.

Upcoming Events

Hospice Care Unveiled: Understanding What It Is (and Isn’t) for AML Patients

Feb 25 / 13:00 EST

Fuel Your Health: Nutrition Strategies & Anemia Insights for MDS Patients

Feb 26 / 16:00 EST

All the HealthTree resources anywhere, anytime.

Download our App

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

HealthTree News

Recent Articles

Findings from an International Phase 3 Trial: Uproleselan for Relapsed/Refractory AML

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

Midostaurin for FLT3-Mutated AML, 10 Years Later

Olutasidenib Study Results for Relapsed/Refractory AML

Study Highlights The Need for Risk Models in AML for Black Patients

HealthTree Foundation Honors Leading Blood Cancer Researchers at ASH 2024 Awards Reception

FDA Approval of Treosulfan for AML and MDS

An Opportunity to Take Action: Regional Cure Teams

Understanding Barriers to CAR T-Cell Therapy for Blood Cancer Patients

Why Should You Quit Smoking If You Have MDS or AML?

Trending Articles

FDA Approval of Treosulfan for AML and MDS

Olutasidenib Study Results for Relapsed/Refractory AML

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

Former NHL Player Kelly Chase Shares an Update on His AML Treatment

Venetoclax Plus 7+3 Chemotherapy: A Promising Induction Therapy for Newly Diagnosed AML

Upcoming Events

Hospice Care Unveiled: Understanding What It Is (and Isn’t) for AML Patients

Fuel Your Health: Nutrition Strategies & Anemia Insights for MDS Patients

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us

HealthTree News

Recent Articles

Findings from an International Phase 3 Trial: Uproleselan for Relapsed/Refractory AML

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

Midostaurin for FLT3-Mutated AML, 10 Years Later

Olutasidenib Study Results for Relapsed/Refractory AML

Study Highlights The Need for Risk Models in AML for Black Patients

HealthTree Foundation Honors Leading Blood Cancer Researchers at ASH 2024 Awards Reception

FDA Approval of Treosulfan for AML and MDS

An Opportunity to Take Action: Regional Cure Teams

Understanding Barriers to CAR T-Cell Therapy for Blood Cancer Patients

Why Should You Quit Smoking If You Have MDS or AML?

Trending Articles

FDA Approval of Treosulfan for AML and MDS

Olutasidenib Study Results for Relapsed/Refractory AML

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

Former NHL Player Kelly Chase Shares an Update on His AML Treatment

Venetoclax Plus 7+3 Chemotherapy: A Promising Induction Therapy for Newly Diagnosed AML

Upcoming Events

Hospice Care Unveiled: Understanding What It Is (and Isn’t) for AML Patients

Fuel Your Health: Nutrition Strategies & Anemia Insights for MDS Patients

Stay Informed. Get the Support You Need for Acute Myeloid Leukemia.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Follow Us